PRACSIS

Their core work

PRACSIS is a Brussels-based innovation intermediary specialising in bridging publicly funded research — particularly in bioeconomy and biotechnology — to commercial, social, and policy applications. Their core work involves designing and running structured support programmes that help EU-funded research teams navigate the path from lab results to market-ready products or policy instruments. They do this through assessment frameworks, mentoring, training, and tailored exploitation support targeted at research consortia that lack in-house commercialisation capacity. In practice, they serve as the connective tissue between scientists with results and the business or policy actors who can use them.

What they specialise in

How they've shifted over time

In their earliest H2020 work (2015–2018), PRACSIS focused on the process side of commercialisation: how to assess, network, mentor, and support bioeconomy research projects as they move toward impact. By their second project (2017–2020), the language shifted decisively toward outcomes — biotechnology, technology transfer, exploitation — suggesting they moved from designing support frameworks to delivering hands-on transfer and cluster-building activities. The direction is clear: from facilitation methodology toward direct exploitation engagement, with biotechnology as the emerging focal technology domain.

PRACSIS appears to be deepening its positioning as a hands-on technology transfer operator in biotechnology, moving beyond process facilitation toward active exploitation and cluster coordination roles.

How they like to work

PRACSIS has participated exclusively as a consortium partner, never leading a project — consistent with a specialist service provider that is brought in for a defined function rather than acting as research coordinator. With only 11 unique partners across 2 projects, their consortium circles are small and focused. This suggests they are engaged selectively, likely for a specific commercialisation or exploitation work package rather than as a broad contributor.

PRACSIS has collaborated with 11 unique partners across 7 countries, a modest but geographically spread European network for an organisation of its size. The multi-country reach — despite only two projects — suggests their consortia were deliberately pan-European, which fits the policy and dissemination nature of CSA projects.

What sets them apart

PRACSIS occupies a specific niche that most research organisations and consultancies do not: they design and run structured pilot programmes to test and accelerate the commercialisation readiness of EU-funded bioeconomy research. Based in Brussels, they are well-positioned to bridge research results with EU policy cycles and funding instruments. For a consortium that has strong science but weak exploitation capacity, PRACSIS brings a tested methodology rather than generic advisory services.

Highlights from their portfolio

• CommBeBiz
  The larger of the two projects (EUR 334,062) and the clearest expression of PRACSIS's core methodology — a structured pilot programme designed to fast-track bioeconomy research projects toward commercial and policy impact.
• KETBIO
  Marks an evolution in PRACSIS's approach, applying a cluster model to key enabling biotechnologies — a signal that they can operate in more structured industry-facing innovation ecosystems beyond broad bioeconomy.